Systematic Assessment of Laryngopharyngeal Function in Patients With Neurodegenerative Diseases

NCT ID: NCT04706234

Last Updated: 2025-04-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

350 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-09-01

Study Completion Date

2028-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a non-interventional observational study designed to systematically record the results of routine laryngeal examinations and specific characteristics of dysphagia in patients with neurodegenerative disorders. The results of a fiberoptic / flexible endoscopic evaluation of swallowing (FEES) while performing a structured task protocol will be recorded. If available, laryngeal electromyography (EMG) results will also be recorded. In addition to the examination results, demographic and disease-specific data are collected, and two questionnaires, the Swallowing Disturbance Questionnaire for Parkinson's Disease (SDQ-PD) and the swallowing specific Quality Of Life Questionnaire (SWALQOL), are administered.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Neurodegenerative disorders are associated with a high prevalence of neurogenic dysphagia. Depending on the underlying disease, the prevalence can affect up to 80% of patients. Dysphagia is associated with dehydration, malnutrition, facilitates aspiration pneumonia and thereby determines the prognosis of neurodegenerative diseases. For most of them, dysphagia-associated complications are the leading cause of death.

Multiple system atrophy (MSA) is a sporadic progressive neurodegenerative disorder caused by oligodendroglial aggregation of α-synuclein affecting predominantly the nigrostriatal, olivo-ponto-cerebellar, and autonomic systems,resulting in a clinical presentation of dysautonomia combined with either predominantly parkinsonian (MSA-P) or cerebellar (MSA-C) symptoms of varying severity.In its early stage, the diagnosis of MSA according to the second consensus criteria can be challenging. Therefore, the Movement Disorders Society MSA study group recently addressed the importance of developing valuable diagnostic tools for securing an early diagnosis in patients with MSA not only to estimate disease prognosis but also to early initiate novel, potentially disease-modifying treatments in clinical trials. Despite laryngopharyngeal dysfunction being associated with decreased life expectancy and quality of life, systematic assessment of these functions in MSA is scarce. Previously, an easy-to-implement MSA-FEES task-protocol was suggested to systematically assess laryngopharyngeal function.

A pilot study on 8 patients with MSA not only showed that the task protocol was feasible and well tolerated, but also that laryngopharyngeal symptoms where highly prevalent despite the lack of clinical presentation (Warnecke et. al 2019). Moreover, irregular arytenoid cartilages movements where present in all MSA-patients when performing this task protocol, suggesting this symptom could serve as a clinical marker to identify MSA-patients. Following this pilot study, an observational two center study assessed 57 MSA patients with this protocol and compared findings to an age-matched cohort of PD-patients (Gandor et al. 2020). While only 43.9% of MSA patients had clinical symptoms of laryngeal dysfunction, 93% showed laryngeal abnormalities during FEES performing the task-protocol. 91.2% of MSA-patients showed irregular arytenoid cartilages movements. In contrast, only one PD patient showed laryngeal abnormalities with vocal fold motion impairment, but not irregular arytenoid cartilages movements. This study suggests that irregular arytenoid cartilages movements allow differentiating MSA from PD with a sensitivity of 0.9 and a specificity of 1.0.

4repeat tauopathies (4RT) are caused by an intraneuronal accumulation of 4repeat tau.

4RT, also known as progressive supranuclear palsy (PSP) with all its clinical subtypes, is a rapidly progressive neurodegenerative disease that leads to increasing impairment of cortical and subcortical function in the affected person due to the accumulation of tau protein in the brain (Höglinger 2017). Due to the clinical variability of the presentation, early diagnostic certainty is desirable. Depending on the affected area in the central nervous system, different clinical phenotypes result. The most commonly described and researched entity is Progressive Supranuclear P, also known as Richardson Syndrome, or PSP-RS. Further clinical presentations include a Parkinsonian variant (PSP-P), corticobasal syndrome (PSP-CBS), pure akinesia with gait freezing (PSP-PAGF), speech/language dominant presentations (PSP-SL), frontotemproal dementia variants (PSP-FTD), and cerebellar presentations (PSP-C) (Höglinger 2017).

4RT is also associated with swallowing and speech problems, and aspiration pneumonia is one of the most common causes of death in this disease entity (Tilley 2016). In addition, dystonic dysinnervation of laryngeal muscles can lead to laryngeal motion abnormalities (Panegyres 2007).

Equally, patients with motor neurone disease (MND) are affected by dysphagia early in the disease. In a FEES study by Steven B. Leder and colleagues (2004), which included 17 ALS patients subjectively complaining of dysphagia, fluid aspiration or an increased risk of fluid aspiration was found in almost 60% of cases, regardless of whether the disease initially mainly affected the bulbar musculature or the limb musculature. As the disease progressed, the depth of penetration of fluids into the hypopharynx prior to triggering the swallowing reflex increased, so these patients were advised to thicken fluids. Initially, residues of solid food consistencies were detected in the valleculae, piriform sinus and/or laryngeal inlet in three patients after swallowing. As a result of progressive paresis of the pharyngeal muscles, the residuals increased in the ALS patients examined during the course of the disease. If this disorder pattern was detected, it was advised to reduce the size of the food bolus and to clear the pharynx by swallowing water or reswallowing several times. In a further small case series (n = 11), the FEES showed that dysphagic ALS patients are particularly at risk of penetration/aspiration when swallowing liquids. Penetration and aspiration occur particularly frequently intradeglutitively (D'Ottaviano et al. 2013). A recent publication reports on FEES examinations in 202 ALS patients (w/m 95/107; bulbar/spinal onset 66/136; mean age 64.68 +/- 11.12 years). A close positive correlation with disease severity (measured using the ALSFRS-R) was found for all FEES parameters (leaking, aspiration, residuals), regardless of the three consistencies tested (liquid, semi-solid, solid) (Fattori et al. 2017).

The aim of this FEEMSA trial is to continue recruitment of patients with neurodegenerative diseases and systematically assess laryngopharyngeal function in large cohorts, to categorise the dysphagia phenotypes and better correlate them with the disease subtypes (MSA Parkinson vs cerebellar; PSP variants, MND variants, etc). If available, laryngeal EMG will also be recorded.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple System Atrophy Parkinson Disease Progressive Supranuclear Palsy Motor Neuron Disease Neurodegenerative Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Multiple System Atrophy

Patients diagnosed will probable or possible MSA according to the 2nd criteria for the diagnosis of MSA (Gilman 2008) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).

No interventions assigned to this group

progressive supranuclear palsy

Patients diagnosed will probable or possible Progressive Supranuclear Palsy or (PSP) related 4repeat tauopathies according to the Movement Disorders Society diagnostic criteria (Höglinger 2017) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).

No interventions assigned to this group

Parkinson Disease

Patients diagnosed will Parkinson's disease according to the Movement Disorders Society diagnostic criteria (Postuma 2015) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).

No interventions assigned to this group

Motor Neuron Disease

Patients diagnosed with Motor Neuron Disease that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).

No interventions assigned to this group

Neurodegenerative Diseases

Patients diagnosed with a neurodegenerative disease not specified above that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of probable or possible multiple system atrophy according to current consensus criteria (Gilman et al. 2008) or
* diagnosis of probable or possible PSP according to the the Movement Disorders Society (MDS) diagnostic criteria (Höglinger et al. 2017) or
* diagnosis of Parkinson's disease according to the MDS diagnostic criteria (Postuma et al 2015)
* Hoehn and Yahr Stage within the range of I-V or
* diagnosis of motor neurone disease or
* diagnosis of a neurodegenerative disease other than specified above

AND underwent laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).

Exclusion Criteria

\- Patients who do not sign the consent form
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Muenster

OTHER

Sponsor Role collaborator

Medical University of Warsaw

OTHER

Sponsor Role collaborator

Hannover Medical School

OTHER

Sponsor Role collaborator

University of Ulm

OTHER

Sponsor Role collaborator

Medical University Innsbruck

OTHER

Sponsor Role collaborator

University Hospital Carl Gustav Carus

OTHER

Sponsor Role collaborator

University of Barcelona

OTHER

Sponsor Role collaborator

Seoul National University Hospital

OTHER

Sponsor Role collaborator

Gifu University Graduate School of Medicine

OTHER

Sponsor Role collaborator

University of Bologna

OTHER

Sponsor Role collaborator

Tel Aviv University

OTHER

Sponsor Role collaborator

Asklepios Kliniken Hamburg GmbH

OTHER

Sponsor Role collaborator

Asklepios Fachklinikum Stadtroda

OTHER

Sponsor Role collaborator

Klinikum Osnabrück

UNKNOWN

Sponsor Role collaborator

Kliniken Beelitz GmbH

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Florin Gandor, MD

Consultant Neurologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Florin Gandor, MD

Role: PRINCIPAL_INVESTIGATOR

Movement Disorders Hospital Beelitz-Heilstätten, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Neurology and Department of ENT, Medical University Innsbruck

Innsbruck, Tyrol, Austria

Site Status RECRUITING

Department of Neurology, Medical University of Ulm

Ulm, Baden-Wurttemberg, Germany

Site Status RECRUITING

Movement Disorders Hospital - Kliniken Beelitz

Beelitz-Heilstätten, Brandenburg, Germany

Site Status RECRUITING

Department of Neurology, Medical School Hannover

Hanover, Lower Saxony, Germany

Site Status RECRUITING

Department of Neurology, University Hospital Münster

Münster, North Rhine-Westphalia, Germany

Site Status RECRUITING

Department of Neurology, University Hospital Carl Gustav Carus

Dresden, Saxony, Germany

Site Status RECRUITING

Department of Neueology Asklepios Klinik Stadtroda

Stadtroda, Thuringia, Germany

Site Status RECRUITING

Asklepios Fachklinikum Stadtroda

Stadtroda, Thuringia, Germany

Site Status RECRUITING

Asklepios Klinik Barmbek

Hamburg, , Germany

Site Status RECRUITING

Department of Neurology Asklepios Klinik Barmbek

Hamburg, , Germany

Site Status RECRUITING

Department of Neurology, Movement Disorders Unit, Medical Center Tel Aviv

Tel Aviv, , Israel

Site Status RECRUITING

IRCCS Istituto delle Scienze Neurologiche, Azienda USL di Bologna

Bologna, , Italy

Site Status RECRUITING

Department of Neurology, Gifu University Graduate School of Medicine

Gifu, , Japan

Site Status RECRUITING

Department of Neurology, Medical University Warsaw

Warsaw, , Poland

Site Status RECRUITING

Department of Neurology SNUCM

Seoul, , South Korea

Site Status RECRUITING

Unidad de Parkinson y Trastornos del Movimiento Instituto Clínic de Neurociencias, Hospital Clinic de Barcelona

Barcelona, Catalonia, Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria Germany Israel Italy Japan Poland South Korea Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Florin Gandor, MD

Role: CONTACT

+493320422781 ext. 22781

Tobias Warnecke, MD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gregor Wenning, MD, PhD, MSc

Role: primary

+43676596 ext. 4772

Alessandra Fanciulli, MD, PhD

Role: backup

+435125048 ext. 3238

Jan Kassubek, MD

Role: primary

Rebecca Kassubek, MD

Role: backup

Florin Gandor, MD

Role: primary

+49332042 ext. 2781

Doreen Gruber, MD

Role: backup

+49332042 ext. 2781

Martin Klietz, MD

Role: primary

Katharina Pannewitz-Makaj, MD

Role: backup

Inga Claus, MD

Role: primary

Björn Falkenburger, MD

Role: primary

+49351458 ext. 2532

Inaki Schniewind, MD

Role: backup

David Weise

Role: primary

+49 36428 56 ext. 1375

David Weise, PD Dr

Role: primary

Peter P Urban, Prof.

Role: primary

Peter Urban, MD

Role: primary

0401818823841

Tanya Gurevich, MD

Role: primary

Adi Ezra

Role: backup

Giulia Giannini, MD, PhD

Role: primary

Luca Baldelli, MD

Role: backup

Takayoshi Shimohata, MD PhD

Role: primary

Kenjiro Kunieda, MD PhD

Role: backup

+81 58 230 6254

Andrzej Friedman, MD, PhD

Role: primary

Natalia Madetko, MD

Role: backup

Kim Han-Joon, MD PhD

Role: primary

Maria J Marti, MD PhD

Role: primary

+34 93 227 57 85

Alexandra Perez, MD

Role: backup

+34 93 227 57 85

References

Explore related publications, articles, or registry entries linked to this study.

Warnecke T, Vogel A, Ahring S, Gruber D, Heinze HJ, Dziewas R, Ebersbach G, Gandor F. The Shaking Palsy of the Larynx-Potential Biomarker for Multiple System Atrophy: A Pilot Study and Literature Review. Front Neurol. 2019 Mar 26;10:241. doi: 10.3389/fneur.2019.00241. eCollection 2019.

Reference Type BACKGROUND
PMID: 30972002 (View on PubMed)

Gandor F, Vogel A, Claus I, Ahring S, Gruber D, Heinze HJ, Dziewas R, Ebersbach G, Warnecke T. Laryngeal Movement Disorders in Multiple System Atrophy: A Diagnostic Biomarker? Mov Disord. 2020 Dec;35(12):2174-2183. doi: 10.1002/mds.28220. Epub 2020 Aug 5.

Reference Type BACKGROUND
PMID: 32757231 (View on PubMed)

Vogel A, Claus I, Ahring S, Gruber D, Haghikia A, Frank U, Dziewas R, Ebersbach G, Gandor F, Warnecke T. Endoscopic Characteristics of Dysphagia in Multiple System Atrophy Compared to Parkinson's Disease. Mov Disord. 2022 Mar;37(3):535-544. doi: 10.1002/mds.28854. Epub 2021 Nov 13.

Reference Type BACKGROUND
PMID: 34773420 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

S21(a)/2017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.